“With multiple potential blockbusters in development, and a track record that proves the company knows how to launch a new drug… [this] stock is probably worth the risk right now,” advises the author of today’s article in regards to the biotech he examines, which, having just launched its first rare disease drug last spring, could receive its fourth new drug approval by the end of this year. For more on this biotech and its “win-win-win solution for rare disease drugmakers, the patients relying on them, and risk weary end payers”, CLICK HERE.
